The metabolic basis of kidney cancer

Linehan, 2003, The genetic basis of cancer of the kidney, Journal of Urology, 170, 2163, 10.1097/01.ju.0000096060.92397.ed Linehan, 2010, The genetic basis of kidney cancer: a metabolic disease, Nature Reviews Urology, 7, 277, 10.1038/nrurol.2010.47 Lonser, 2003, von Hippel–Lindau disease, Lancet, 361, 2059, 10.1016/S0140-6736(03)13643-4 Wong, 2007, Genotype-phenotype correlation in von Hippel–Lindau disease with retinal angiomatosis, Archives of Ophthalmology, 125, 239, 10.1001/archopht.125.2.239 Filling-Katz, 1991, Central nervous system involvement in von Hippel–Lindau disease, Neurology, 41, 41, 10.1212/WNL.41.1.41 Choo, 2004, Endolymphatic sac tumors in von Hippel–Lindau disease, Journal of Neurosurgery, 100, 480, 10.3171/jns.2004.100.3.0480 Choyke, 1997, Epididymal cystadenomas in von Hippel–Lindau disease, Urology, 49, 926, 10.1016/S0090-4295(97)00074-5 Libutti, 1998, Pancreatic neuroendocrine tumors associated with von Hippel–Lindau disease: diagnostic and management recommendations, Surgery, 124, 1153, 10.1067/msy.1998.91823 Blansfield, 2007, Clinical, genetic and radiographic analysis of 108 patients with von Hippel–Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs), Surgery, 142, 814, 10.1016/j.surg.2007.09.012 Poston, 1995, Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel–Lindau disease: clinical and molecular genetic implications, Journal of Urology, 153, 22, 10.1097/00005392-199501000-00009 Walther, 1995, Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel–Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications, Journal of Urology, 154, 2010, 10.1016/S0022-5347(01)66674-6 Walther, 1999, Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery, Journal of Urology, 161, 1475, 10.1016/S0022-5347(05)68930-6 Herring, 2001, Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience, Journal of Urology, 165, 777, 10.1016/S0022-5347(05)66524-X Duffey, 2004, The relationship between renal tumor size and metastases in patients with von Hippel–Lindau disease, Journal of Urology, 172, 63, 10.1097/01.ju.0000132127.79974.3f Hosoe, 1990, Localization of the von Hippel–Lindau disease gene to a small region of chromosome 3, Genomics, 8, 634, 10.1016/0888-7543(90)90249-T Latif, 1993, Identification of the von Hippel–Lindau disease tumor suppressor gene, Science, 260, 1317, 10.1126/science.8493574 Stolle, 1998, Improved detection of germline mutations in the von Hippel–Lindau disease tumor suppressor gene, Human Mutation, 12, 417, 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K Nickerson, 2008, Improved identification of von Hippel–Lindau gene alterations in clear cell renal tumors, Clinical Cancer Research, 14, 4726, 10.1158/1078-0432.CCR-07-4921 Moore, 2011, Von Hippel–Lindau (VHL) inactivation in sporadic clear cell renal cancer: Associations with germline VHL polymorphisms and etiologic risk factors, PLoS Genetics, 7, 1, 10.1371/journal.pgen.1002312 Duan, 1995, Inhibition of transcription elongation by the VHL tumor suppressor protein, Science, 269, 1402, 10.1126/science.7660122 Pause, 1997, The von Hippel–Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins, Proceedings of the National Academy of Sciences of the United States of America, 94, 2156, 10.1073/pnas.94.6.2156 Kibel, 1995, Binding of the von Hippel–Lindau tumor suppressor protein to elongin B and C, Science, 269, 1444, 10.1126/science.7660130 Kamura, 1999, Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase, Science, 284, 657, 10.1126/science.284.5414.657 Maxwell, 1999, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis, Nature, 399, 271, 10.1038/20459 Ohh, 2000, Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel–Lindau protein, Nature Cell Biology, 2, 423, 10.1038/35017054 Jaakkola, 2001, Targeting of HIF-alpha to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation, Science, 292, 468, 10.1126/science.1059796 Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, New England Journal of Medicine, 349, 427, 10.1056/NEJMoa021491 Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, New England Journal of Medicine, 356, 115, 10.1056/NEJMoa065044 Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, New England Journal of Medicine, 356, 125, 10.1056/NEJMoa060655 Hudes, 2007, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, New England Journal of Medicine, 356, 2271, 10.1056/NEJMoa066838 Motzer, 2008, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, Lancet, 372, 1432, 10.1016/S0140-6736(08)61039-9 Sternberg, 2010, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial, Journal of Clinical Oncology, 28, 1061, 10.1200/JCO.2009.23.9764 Zbar, 1994, Hereditary papillary renal cell carcinoma, Journal of Urology, 151, 561, 10.1016/S0022-5347(17)35015-2 Lubensky, 1999, Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype, American Journal of Pathology, 155, 517, 10.1016/S0002-9440(10)65147-4 Ornstein, 2000, Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer, Journal of Urology, 163, 431, 10.1016/S0022-5347(05)67893-7 Schmidt, 1997, Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas, Nature Genetics, 16, 68, 10.1038/ng0597-68 Schmidt, 2004, Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the Met proto-oncogene, Journal of Urology, 172, 1256, 10.1097/01.ju.0000139583.63354.e0 Esteve-Puig, 2009, Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF, PLoS ONE, 4, e4771, 10.1371/journal.pone.0004771 Jones, 2009, Tumor suppressors and cell metabolism: a recipe for cancer growth, Genes and Development, 23, 537, 10.1101/gad.1756509 Srinivasan, 2008, A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC), Journal of Clinical Oncology, 26, 5103, 10.1200/jco.2008.26.15_suppl.5103 Birt, 1977, Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons, Archives of Dermatology, 113, 1674, 10.1001/archderm.1977.01640120042005 Toro, 2007, Lung cysts, spontaneous pneumothrorax and genetic associations in 89 families with Birt–Hogg–Dubé syndrome, American Journal of Respiratory and Critical Care Medicine, 175, 1044, 10.1164/rccm.200610-1483OC Zbar, 2002, Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt–Hogg–Dubé syndrome, Cancer Epidemiology, Biomarkers and Prevention, 11, 393 Pavlovich, 2002, Renal tumors in the Birt–Hogg–Dubé syndrome, American Journal of Surgical Pathology, 26, 1542, 10.1097/00000478-200212000-00002 Nickerson, 2002, Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt–Hogg–Dubé syndrome, Cancer Cell, 2, 157, 10.1016/S1535-6108(02)00104-6 Toro, 2008, BHD mutations, clinical and molecular genetic investigations of Birt–Hogg–Dubé syndrome: a new series of 50 families and a review of published reports, Journal of Medical Genetics, 45, 321, 10.1136/jmg.2007.054304 Vocke, 2005, High frequency of somatic frameshift BHD gene mutations in Birt–Hogg–Dubé-associated renal tumors, Journal of the National Cancer Institute, 97, 931, 10.1093/jnci/dji154 Baba, 2006, Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling, Proceedings of the National Academy of Sciences of the United States of America, 103, 15552, 10.1073/pnas.0603781103 Hasumi, 2008, Identification and characterization of a novel folliculin-interacting protein FNIP2, Gene, 415, 60, 10.1016/j.gene.2008.02.022 Hasumi, 2009, Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2, Proceedings of the National Academy of Sciences of the United States of America, 106, 18722, 10.1073/pnas.0908853106 Hong, 2010, Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization, PLoS ONE, 5, e15793, 10.1371/journal.pone.0015793 Baba, 2008, Kidney-targeted Birt–Hogg–Dubé gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys, Journal of the National Cancer Institute, 100, 140, 10.1093/jnci/djm288 Malouf, 2011, Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors, Journal of Urology, 185, 24, 10.1016/j.juro.2010.08.092 Shipley, 1995, Mapping the X chromosome breakpoint in two papillary renal cell carcinoma cell lines with a t(X;1)(p11.2;q21.2) and the first report of a female case, Cytogenetics and Cell Genetics, 71, 280, 10.1159/000134127 Sidhar, 1996, The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 tanscription factor gene, Human Molecular Genetics, 5, 1333, 10.1093/hmg/5.9.1333 Weterman, 1996, Molecular cloning of the papillary renal cell carcinoma-associated translocation (X;1)(p11;q21) breakpoint, Cytogenetics and Cell Genetics, 75, 2, 10.1159/000134444 Clark, 1997, Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma, Oncogene, 15, 2233, 10.1038/sj.onc.1201394 Argani, 2010, Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers, American Journal of Surgical Pathology, 34, 1295, 10.1097/PAS.0b013e3181e8ce5b Zhong, 2010, Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma, American Journal of Surgical Pathology, 34, 757, 10.1097/PAS.0b013e3181dd577e Argani, 2002, PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21), American Journal of Surgical Pathology, 26, 1553, 10.1097/00000478-200212000-00003 Armah, 2010, Xp11.2 translocation renal cell carcinoma, Archives of Pathology & Laboratory Medicine, 134, 124, 10.5858/2008-0391-RSR.1 Argani, 2001, A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation, American Journal of Pathology, 158, 2089, 10.1016/S0002-9440(10)64680-9 Davis, 2003, Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation, Proceedings of the National Academy of Sciences of the United States of America, 100, 6051, 10.1073/pnas.0931430100 Maubec, 2010, Characteristics of the coexistence of melanoma and renal cell carcinoma, Cancer, 116, 5716, 10.1002/cncr.25562 Bertolotto, 2011, A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma, Nature, 10.1038/nature10539 Cheli, 2010, Fifteen-year quest for microphthalmia-associated transcription factor target genes, Pigment Cell and Melanoma Research, 23, 27, 10.1111/j.1755-148X.2009.00653.x Malouf, 2010, Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network, Annals of Oncology, 21, 1834, 10.1093/annonc/mdq029 Crino, 2006, The tuberous sclerosis complex, New England Journal of Medicine, 355, 1345, 10.1056/NEJMra055323 Bjornsson, 1996, Tuberous sclerosis-associated renal cell carcinoma clinical, pathological, and genetic features, American Journal of Pathology, 149, 1 Brugarolas, 2003, TSC2 regulates VEGF through mTOR-dependent and -independent pathways, Cancer Cell, 4, 147, 10.1016/S1535-6108(03)00187-9 Brugarolas, 2004, Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes, Cancer Cell, 6, 7, 10.1016/j.ccr.2004.06.020 Bissler, 2008, Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis, New England Journal of Medicine, 358, 140, 10.1056/NEJMoa063564 Gustafson, 2007, Cowden syndrome, Seminars in Oncology, 34, 428, 10.1053/j.seminoncol.2007.07.009 Blumenthal, 2008, PTEN hamartoma tumor syndromes, European Journal of Human Genetics, 16, 1289, 10.1038/ejhg.2008.162 Eng, 2003, PTEN: one gene, many syndromes, Human Mutation, 22, 183, 10.1002/humu.10257 Squarize, 2008, Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin, Cancer Research, 68, 7066, 10.1158/0008-5472.CAN-08-0922 Warburg, 1924, Metabolism of the carcinoma cell, Biochemische Zeitschrift, 152, 309 Warburg, 1956, On the origin of cancer cells, Science, 123, 309, 10.1126/science.123.3191.309 Launonen, 2001, Inherited susceptibility to uterine leiomyomas and renal cell cancer, Proceedings of the National Academy of Sciences of the United States of America, 98, 3387, 10.1073/pnas.051633798 Zbar, 1995, Hereditary papillary renal cell carcinoma: clinical studies in 10 families, Journal of Urology, 153, 907, 10.1016/S0022-5347(01)67601-8 Toro, 2003, Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America, American Journal of Human Genetics, 73, 95, 10.1086/376435 Merino, 2007, The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome, American Journal of Surgical Pathology, 31, 1578, 10.1097/PAS.0b013e31804375b8 Grubb, 2007, Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer, Journal of Urology, 177, 2074, 10.1016/j.juro.2007.01.155 Tomlinson, 2002, Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer, Nature Genetics, 30, 406, 10.1038/ng849 Isaacs, 2005, HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability, Cancer Cell, 8, 143, 10.1016/j.ccr.2005.06.017 Tong, 2011, The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases metabolic propensities and lowers cellular iron levels, Cancer Cell, 20, 315, 10.1016/j.ccr.2011.07.018 Yang, 2010, UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer, Cancer Genetics and Cytogenetics, 196, 45, 10.1016/j.cancergencyto.2009.08.018 Baysal, 2000, Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma, Science, 287, 848, 10.1126/science.287.5454.848 Niemann, 2000, Mutations in SDHC cause autosomal dominant paraganglioma, type 3, Nature Genetics, 26, 268, 10.1038/81551 Eng, 2003, A role for mitochondrial enzymes in inherited neoplasia and beyond, Nature Reviews Cancer, 3, 193, 10.1038/nrc1013 Neumann, 2004, Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations, JAMA, 292, 943, 10.1001/jama.292.8.943 Vanharanta, 2004, Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma, American Journal of Human Genetics, 74, 153, 10.1086/381054 Ricketts, 2008, Germline SDHB mutations and familial renal cell carcinoma, Journal of the National Cancer Institute, 100, 1260, 10.1093/jnci/djn254 Henderson, 2009, SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis, Familial Cancer, 8, 257, 10.1007/s10689-009-9234-z